You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCyclophosphamide
Accession NumberDB00531  (APRD00408)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionPrecursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]
Structure
Thumb
Synonyms
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamidum
Cytophosphane
Ledoxina
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
External Identifiers
  • B 518
  • NSC 26271
  • RCRA Waste Number U058
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cyclophosphamidecapsule25 mg/1oralRoxane Laboratories, Inc.2013-09-16Not applicableUs
Cyclophosphamideinjection, powder, lyophilized, for solution2 g/100mLintravenous; oralBaxter Healthcare Corporation1959-11-16Not applicableUs
Cyclophosphamidecapsule50 mg/1oralRoxane Laboratories, Inc.2013-09-16Not applicableUs
Cyclophosphamidecapsule25 mg/1oralAvera Mc Kennan Hospital2015-08-18Not applicableUs
Cyclophosphamideinjection, powder, lyophilized, for solution500 mg/25mLintravenous; oralBaxter Healthcare Corporation1959-11-16Not applicableUs
Cyclophosphamidecapsule50 mg/1oralAvera Mc Kennan Hospital2015-04-23Not applicableUs
Cyclophosphamideinjection, powder, lyophilized, for solution1 g/50mLintravenous; oralBaxter Healthcare Corporation1959-11-16Not applicableUs
Cytoxan Pws for Inj 1000mg/vialpowder for solution1000 mgintravenousBristol Myers Squibb Canada1990-12-312008-10-17Canada
Cytoxan Pws for Inj 2000mg/vialpowder for solution2000 mgintravenousBristol Myers Squibb Canada1990-12-312008-10-17Canada
Cytoxan Tab 25mgtablet25 mgoralBristol Myers Squibb Canada1977-12-312008-11-21Canada
Cytoxan Tab 50mgtablet50 mgoralBristol Myers Squibb Canada1976-12-312009-01-22Canada
Procytox 1000mg/vialpowder for solution1000 mgintravenousBaxter Corporation2003-11-18Not applicableCanada
Procytox 2000mg/vialpowder for solution2000 mgintravenousBaxter Corporation2003-11-03Not applicableCanada
Procytox 200mg/vialpowder for solution200 mgintravenousBaxter Corporation2000-11-26Not applicableCanada
Procytox 500mg/vialpowder for solution500 mgintravenousBaxter Corporation2000-10-26Not applicableCanada
Procytox Pws 500mgpowder for solution500 mgparenteral (unspecified)Carter Horner Corp.1977-12-312000-11-17Canada
Procytox Tab 25mgtablet25 mgoralBaxter Corporation2000-09-01Not applicableCanada
Procytox Tab 25mgtablet25 mgoralCarter Horner Corp.1973-12-312001-05-22Canada
Procytox Tab 50mgtablet50 mgoralBaxter Corporation2000-08-22Not applicableCanada
Procytox Tablets 50mgtablet50 mgoralCarter Horner Corp.1959-12-312001-05-22Canada
Procytox Vial 1000mgpowder for solution1 gintravenousCarter Horner Corp.1966-12-312001-05-22Canada
Procytox Vial 200mgpowder for solution200 mgintravenousCarter Horner Corp.1959-12-312000-11-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cyclophosphamideinjection, powder, for solution2 g/100mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Cyclophosphamidetablet25 mg/1oralRoxane Laboratories, Inc.1999-08-17Not applicableUs
Cyclophosphamideinjection, powder, for solution1 g/50mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Cyclophosphamideinjection, powder, for solution500 mg/25mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Cyclophosphamideinjection, powder, for solution2 g/100mLintravenous; oralSandoz Inc.2014-10-31Not applicableUs
Cyclophosphamideinjection, powder, for solution500 mg/25mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Cyclophosphamidetablet50 mg/1oralRoxane Laboratories, Inc.1999-08-17Not applicableUs
Cyclophosphamideinjection, powder, for solution2 g/100mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Cyclophosphamideinjection, powder, for solution1 g/50mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Cyclophosphamideinjection, powder, for solution500 mg/25mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Cyclophosphamideinjection, powder, for solution1 g/50mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Cyclophosphamideinjection, powder, for solution500 mg/25mLintravenous; oralSandoz Inc.2014-10-31Not applicableUs
Cyclophosphamidetablet50 mg/1oralPhysicians Total Care, Inc.1999-08-17Not applicableUs
Cyclophosphamideinjection, powder, for solution2 g/100mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Cyclophosphamideinjection, powder, for solution1 g/50mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Cyclophosphamideinjection, powder, for solution2 g/100mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Cyclophosphamideinjection, powder, for solution1 g/50mLintravenous; oralSandoz Inc.2014-10-31Not applicableUs
Cyclophosphamidetablet25 mg/1oralPhysicians Total Care, Inc.1999-08-17Not applicableUs
Cyclophosphamideinjection, powder, for solution500 mg/25mLintravenous; oralBaxter Healthcare Corporation2008-05-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CytoxanBristol-Myers Squibb
EndoxanActavis
NeosarNot Available
ProcytoxBaxter
RevimmuneNot Available
SendoxanBaxter
Brand mixtures
NameLabellerIngredients
Procytox for Injection 2000mg Pws IVCarter Horner Corp.
Salts
Name/CASStructureProperties
Cyclophosphamide monohydrate
6055-19-2
Thumb
  • InChI Key: PWOQRKCAHTVFLB-UHFFFAOYSA-N
  • Monoisotopic Mass: 278.0353848
  • Average Mass: 279.1
DBSALT001814
Categories
UNII6UXW23996M
CAS number50-18-0
WeightAverage: 261.086
Monoisotopic: 260.02481966
Chemical FormulaC7H15Cl2N2O2P
InChI KeyInChIKey=CMSMOCZEIVJLDB-UHFFFAOYSA-N
InChI
InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
IUPAC Name
2-[bis(2-chloroethyl)amino]-1,3,2λ⁵-oxazaphosphinan-2-one
SMILES
ClCCN(CCCl)P1(=O)NCCCO1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as nitrogen mustard compounds. These are compounds having two beta-haloalkyl groups bound to a nitrogen atom.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassNitrogen mustard compounds
Sub ClassNot Available
Direct ParentNitrogen mustard compounds
Alternative Parents
Substituents
  • Nitrogen mustard
  • Phosphoric monoester diamide
  • Oxazaphosphinane
  • Organic phosphoric acid derivative
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organochloride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl chloride
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationCyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
PharmacodynamicsCyclophosphamide is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.
Mechanism of actionAlkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.
Related Articles
AbsorptionAfter oral administration, peak concentrations occur at one hour.
Volume of distribution

30-50 L

Protein binding20% of cyclophosphamide is protein bound with no dose dependent changes. Some metabolites are protein bound to an extent greater than 60%.
Metabolism

Metabolism and activation occurs at the liver. 75% of the drug is activated by cytochrome P450 isoforms, CYP2A6, 2B6, 3A4, 3A5, 2C9, 2C18, and 2C19. The CYP2B6 isoform is the enzyme with the highest 4-hydroxylase activity. Cyclophosphamide undergoes activation to eventually form active metabolites, phosphoramide mustard and acrolein. Cyclophosphamide appears to induce its own metabolism which results in an overall increase in clearance, increased formation of 4-hydroxyl metabolites, and shortened t1/2 values following repeated administration.

SubstrateEnzymesProduct
Cyclophosphamide
4-HydroxycyclophosphamideDetails
Cyclophosphamide
Dechloroethyl cyclophosphamideDetails
Cyclophosphamide
ChloroacetaldehydeDetails
4-Hydroxycyclophosphamide
4-KetocyclophosphamideDetails
4-Hydroxycyclophosphamide
Not Available
AldophosphamideDetails
Aldophosphamide
Not Available
CarboxyphosphamideDetails
Aldophosphamide
AlcophosphamideDetails
Aldophosphamide
CarboxyphosphamideDetails
Carboxyphosphamide
Not Available
Nornitrogen mustardDetails
Aldophosphamide
Not Available
AcroleinDetails
Acrolein
Acrylic AcidDetails
Aldophosphamide
Not Available
Phosphoramide MustardDetails
Phosphoramide Mustard
Not Available
Phosphoramide AziridiniumDetails
Route of eliminationCyclophosphamide is eliminated primarily in the form of metabolites. 10-20% is excreted unchanged in the urine and 4% is excreted in the bile following IV administration.
Half life3-12 hours
Clearance

Total body clearance = 63 ± 7.6 L/kg.

ToxicityAdverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Cyclophosphamide Action PathwayDrug actionSMP00447
Cyclophosphamide Metabolism PathwayDrug metabolismSMP00604
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 3A4
Gene symbol: CYP3A4
UniProt: P08684
rs2740574 CYP3A4 *1BG AllelleDecreased activation of cyclophosphamide most likely contributing to worse disease free survival in adjuvant chemotherapy for node-positive breast cancer20459744
Cytochrome P450 2B6
Gene symbol: CYP2B6
UniProt: P20813
Not AvailableCYP2B6*1GC AllelleDecreased activation of cyclophosphamide contributing to less adverse reactions (leukocytopenia)17502835
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9722
Blood Brain Barrier+0.971
Caco-2 permeable-0.5451
P-glycoprotein substrateNon-substrate0.71
P-glycoprotein inhibitor INon-inhibitor0.779
P-glycoprotein inhibitor IINon-inhibitor0.9797
Renal organic cation transporterNon-inhibitor0.8125
CYP450 2C9 substrateNon-substrate0.7856
CYP450 2D6 substrateNon-substrate0.5884
CYP450 3A4 substrateSubstrate0.5461
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9232
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9737
Ames testAMES toxic0.9146
CarcinogenicityNon-carcinogens0.8727
BiodegradationNot ready biodegradable0.9511
Rat acute toxicity3.3855 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8419
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Baxter healthcare corp
  • Baxter healthcare corp anesthesia and critical care
  • Teva parenteral medicines inc
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral25 mg/1
Capsuleoral50 mg/1
Injection, powder, for solutionintravenous; oral1 g/50mL
Injection, powder, for solutionintravenous; oral2 g/100mL
Injection, powder, for solutionintravenous; oral500 mg/25mL
Injection, powder, lyophilized, for solutionintravenous; oral1 g/50mL
Injection, powder, lyophilized, for solutionintravenous; oral2 g/100mL
Injection, powder, lyophilized, for solutionintravenous; oral500 mg/25mL
Tabletoral25 mg/1
Tabletoral50 mg/1
Powder for solutionintravenous1000 mg
Powder for solutionintravenous2000 mg
Powder for solutionintravenous200 mg
Powder for solutionintravenous500 mg
Powder for solutionintravenous
Powder for solutionparenteral (unspecified)500 mg
Tabletoral25 mg
Tabletoral50 mg
Powder for solutionintravenous1 g
Prices
Unit descriptionCostUnit
Cyclophosphamide 500 mg vial37.76USD vial
Cyclophosphamide 100% powder33.66USD g
Cytoxan 500 mg vial15.25USD vial
Cytoxan 50 mg tablet4.14USD tablet
Cyclophosphamide 50 mg tablet3.92USD tablet
Cytoxan 25 mg tablet2.26USD tablet
Cyclophosphamide 25 mg tablet2.09USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point48-49Arnold, H., Brock, N. and Bourseaux, F.; U S . Patent 3,018,302; January 23,1962; assigned to Asta-Werke A.G. Chemische Fabrik (W. Germany).
water solubilitySoluble. 1-5 g/100 mL at 23 °CNot Available
logP0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility15.1 mg/mLALOGPS
logP0.76ALOGPS
logP0.097ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)12.78ChemAxon
pKa (Strongest Basic)-0.57ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.57 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity58.48 m3·mol-1ChemAxon
Polarizability23.72 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.91 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-08fr-9470000000-53f4a8ff83c415492e03View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

Riccardo Dalla-Favera, Alessandro Massimo Gianni, “Retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs.” U.S. Patent US6268138, issued March, 1999.

US6268138
General References
  1. Brock N: The history of the oxazaphosphorine cytostatics. Cancer. 1996 Aug 1;78(3):542-7. [PubMed:8697402 ]
  2. Brock N: Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture. Cancer Res. 1989 Jan 1;49(1):1-7. [PubMed:2491747 ]
External Links
ATC CodesL01AA01
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (76.1 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Cyclophosphamide.
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideCyclophosphamide may increase the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.
2-MethoxyestradiolCyclophosphamide may increase the cardiotoxic activities of 2-Methoxyestradiol.
3-MethoxybenzamideCyclophosphamide may increase the cardiotoxic activities of 3-Methoxybenzamide.
3,4-DichloroisocoumarinThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Cyclophosphamide.
3,4-Dihydroxybenzoic AcidCyclophosphamide may increase the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe risk or severity of adverse effects can be increased when 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE is combined with Cyclophosphamide.
5,10-Dideazatetrahydrofolic AcidCyclophosphamide may increase the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.
7-HydroxystaurosporineCyclophosphamide may increase the cardiotoxic activities of 7-Hydroxystaurosporine.
8-azaguanineCyclophosphamide may increase the cardiotoxic activities of 8-azaguanine.
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineCyclophosphamide may increase the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.
AbirateroneCyclophosphamide may increase the cardiotoxic activities of Abiraterone.
AbirateroneThe serum concentration of Cyclophosphamide can be increased when it is combined with Abiraterone.
ABT-263Cyclophosphamide may increase the cardiotoxic activities of ABT-263.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Cyclophosphamide.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Cyclophosphamide.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Cyclophosphamide.
AfatinibCyclophosphamide may increase the cardiotoxic activities of Afatinib.
AfimoxifeneCyclophosphamide may increase the cardiotoxic activities of Afimoxifene.
AfliberceptCyclophosphamide may increase the cardiotoxic activities of Aflibercept.
AlatrofloxacinCyclophosphamide may increase the cardiotoxic activities of Alatrofloxacin.
AlbendazoleCyclophosphamide may increase the cardiotoxic activities of Albendazole.
AldesleukinCyclophosphamide may increase the cardiotoxic activities of Aldesleukin.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Cyclophosphamide.
AlemtuzumabCyclophosphamide may increase the cardiotoxic activities of Alemtuzumab.
AlitretinoinCyclophosphamide may increase the cardiotoxic activities of Alitretinoin.
AllopurinolThe risk or severity of adverse effects can be increased when Allopurinol is combined with Cyclophosphamide.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Cyclophosphamide.
Alpha-1-proteinase inhibitorThe risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Cyclophosphamide.
Alpha-DifluoromethylornithineCyclophosphamide may increase the cardiotoxic activities of Alpha-Difluoromethylornithine.
AltretamineCyclophosphamide may increase the cardiotoxic activities of Altretamine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Cyclophosphamide.
AminoglutethimideCyclophosphamide may increase the cardiotoxic activities of Aminoglutethimide.
Aminolevulinic acidCyclophosphamide may increase the cardiotoxic activities of Aminolevulinic acid.
AmiodaroneThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Amiodarone.
AmiodaroneThe metabolism of Cyclophosphamide can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Cyclophosphamide.
AmonafideCyclophosphamide may increase the cardiotoxic activities of Amonafide.
AmprenavirThe risk or severity of adverse effects can be increased when Amprenavir is combined with Cyclophosphamide.
AmrubicinCyclophosphamide may increase the cardiotoxic activities of Amrubicin.
AmsacrineCyclophosphamide may increase the cardiotoxic activities of Amsacrine.
AnagrelideCyclophosphamide may increase the cardiotoxic activities of Anagrelide.
AnastrozoleCyclophosphamide may increase the cardiotoxic activities of Anastrozole.
annamycinCyclophosphamide may increase the cardiotoxic activities of annamycin.
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Cyclophosphamide.
AP 12009Cyclophosphamide may increase the cardiotoxic activities of AP 12009.
AP24534Cyclophosphamide may increase the cardiotoxic activities of AP24534.
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Cyclophosphamide.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Cyclophosphamide.
AprepitantThe serum concentration of Cyclophosphamide can be increased when it is combined with Aprepitant.
AprotininThe risk or severity of adverse effects can be increased when Aprotinin is combined with Cyclophosphamide.
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Cyclophosphamide.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Cyclophosphamide.
ArmodafinilThe metabolism of Cyclophosphamide can be decreased when combined with Armodafinil.
Arsenic trioxideCyclophosphamide may increase the cardiotoxic activities of Arsenic trioxide.
ArtemetherThe metabolism of Cyclophosphamide can be decreased when combined with Artemether.
ASA404Cyclophosphamide may increase the cardiotoxic activities of ASA404.
AsparaginaseCyclophosphamide may increase the cardiotoxic activities of Asparaginase.
AsunaprevirThe risk or severity of adverse effects can be increased when Asunaprevir is combined with Cyclophosphamide.
AT-101Cyclophosphamide may increase the cardiotoxic activities of AT-101.
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Cyclophosphamide.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Cyclophosphamide.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Cyclophosphamide.
AtomoxetineThe metabolism of Cyclophosphamide can be decreased when combined with Atomoxetine.
AxitinibCyclophosphamide may increase the cardiotoxic activities of Axitinib.
AzacitidineCyclophosphamide may increase the cardiotoxic activities of Azacitidine.
AzathioprineCyclophosphamide may increase the cardiotoxic activities of Azathioprine.
AzathioprineAzathioprine may increase the hepatotoxic activities of Cyclophosphamide.
AZD2171Cyclophosphamide may increase the cardiotoxic activities of AZD2171.
Azelaic AcidCyclophosphamide may increase the cardiotoxic activities of Azelaic Acid.
BatimastatThe risk or severity of adverse effects can be increased when Batimastat is combined with Cyclophosphamide.
BatimastatCyclophosphamide may increase the cardiotoxic activities of Batimastat.
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with Cyclophosphamide.
BelinostatCyclophosphamide may increase the cardiotoxic activities of Belinostat.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Cyclophosphamide.
BendamustineCyclophosphamide may increase the cardiotoxic activities of Bendamustine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cyclophosphamide.
BenzamidineThe risk or severity of adverse effects can be increased when Benzamidine is combined with Cyclophosphamide.
BesifloxacinCyclophosphamide may increase the cardiotoxic activities of Besifloxacin.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Cyclophosphamide.
BetaxololThe metabolism of Cyclophosphamide can be decreased when combined with Betaxolol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Cyclophosphamide.
BexaroteneCyclophosphamide may increase the cardiotoxic activities of Bexarotene.
BexaroteneThe serum concentration of Cyclophosphamide can be decreased when it is combined with Bexarotene.
BicalutamideCyclophosphamide may increase the cardiotoxic activities of Bicalutamide.
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Cyclophosphamide.
BleomycinCyclophosphamide may increase the cardiotoxic activities of Bleomycin.
BlinatumomabCyclophosphamide may increase the cardiotoxic activities of Blinatumomab.
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Cyclophosphamide.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Cyclophosphamide.
BortezomibCyclophosphamide may increase the cardiotoxic activities of Bortezomib.
BortezomibThe metabolism of Cyclophosphamide can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Cyclophosphamide can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cyclophosphamide.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cyclophosphamide.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Cyclophosphamide.
BSI-201Cyclophosphamide may increase the cardiotoxic activities of BSI-201.
BupropionThe metabolism of Cyclophosphamide can be decreased when combined with Bupropion.
BusulfanCyclophosphamide may increase the cardiotoxic activities of Busulfan.
CabazitaxelCyclophosphamide may increase the cardiotoxic activities of Cabazitaxel.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cyclophosphamide.
CabergolineCyclophosphamide may increase the cardiotoxic activities of Cabergoline.
CabozantinibCyclophosphamide may increase the cardiotoxic activities of Cabozantinib.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Cyclophosphamide.
CalcipotriolCyclophosphamide may increase the cardiotoxic activities of Calcipotriol.
CamptothecinCyclophosphamide may increase the cardiotoxic activities of Camptothecin.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Cyclophosphamide.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Cyclophosphamide.
CapecitabineCyclophosphamide may increase the cardiotoxic activities of Capecitabine.
CapecitabineThe metabolism of Cyclophosphamide can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Cyclophosphamide.
CarbamazepineThe metabolism of Cyclophosphamide can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Cyclophosphamide.
CarboplatinCyclophosphamide may increase the cardiotoxic activities of Carboplatin.
CarfilzomibCyclophosphamide may increase the cardiotoxic activities of Carfilzomib.
CarmofurCyclophosphamide may increase the cardiotoxic activities of Carmofur.
CarmustineCyclophosphamide may increase the cardiotoxic activities of Carmustine.
CatumaxomabCyclophosphamide may increase the cardiotoxic activities of Catumaxomab.
CB1954Cyclophosphamide may increase the cardiotoxic activities of CB1954.
CelecoxibCyclophosphamide may increase the cardiotoxic activities of Celecoxib.
CelecoxibThe metabolism of Cyclophosphamide can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Cyclophosphamide can be increased when it is combined with Ceritinib.
CeritinibCyclophosphamide may increase the cardiotoxic activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cyclophosphamide.
CetuximabCyclophosphamide may increase the cardiotoxic activities of Cetuximab.
ChlorambucilCyclophosphamide may increase the cardiotoxic activities of Chlorambucil.
ChloramphenicolThe metabolism of Cyclophosphamide can be decreased when combined with Chloramphenicol.
ChloroquineThe metabolism of Cyclophosphamide can be decreased when combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cyclophosphamide.
ChlorotrianiseneCyclophosphamide may increase the cardiotoxic activities of Chlorotrianisene.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Cyclophosphamide.
ChlorpromazineThe metabolism of Cyclophosphamide can be decreased when combined with Chlorpromazine.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Cyclophosphamide.
CholecalciferolThe metabolism of Cyclophosphamide can be decreased when combined with Cholecalciferol.
ChymostatinThe risk or severity of adverse effects can be increased when Chymostatin is combined with Cyclophosphamide.
CilastatinThe risk or severity of adverse effects can be increased when Cilastatin is combined with Cyclophosphamide.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Cyclophosphamide.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Cyclophosphamide.
CimetidineThe metabolism of Cyclophosphamide can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Cyclophosphamide can be decreased when combined with Cinacalcet.
CinoxacinCyclophosphamide may increase the cardiotoxic activities of Cinoxacin.
CiprofloxacinCyclophosphamide may increase the cardiotoxic activities of Ciprofloxacin.
CisplatinCyclophosphamide may increase the cardiotoxic activities of Cisplatin.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Cyclophosphamide.
CitalopramThe metabolism of Cyclophosphamide can be decreased when combined with Citalopram.
CladribineCyclophosphamide may increase the cardiotoxic activities of Cladribine.
ClarithromycinThe metabolism of Cyclophosphamide can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Cyclophosphamide.
ClemastineThe metabolism of Cyclophosphamide can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Cyclophosphamide.
ClobazamThe metabolism of Cyclophosphamide can be decreased when combined with Clobazam.
ClofarabineCyclophosphamide may increase the cardiotoxic activities of Clofarabine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Cyclophosphamide.
ClomipramineThe metabolism of Cyclophosphamide can be decreased when combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Cyclophosphamide.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Cyclophosphamide.
ClopidogrelThe metabolism of Cyclophosphamide can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Cyclophosphamide can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Clozapine.
ClozapineThe metabolism of Cyclophosphamide can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Cyclophosphamide can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Cyclophosphamide.
CocaineThe metabolism of Cyclophosphamide can be decreased when combined with Cocaine.
ColchicineCyclophosphamide may increase the cardiotoxic activities of Colchicine.
ConivaptanThe serum concentration of Cyclophosphamide can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Cyclophosphamide.
CrizotinibCyclophosphamide may increase the cardiotoxic activities of Crizotinib.
CrizotinibThe metabolism of Cyclophosphamide can be decreased when combined with Crizotinib.
CyclosporineCyclophosphamide may increase the immunosuppressive activities of Cyclosporine.
CyclosporineThe metabolism of Cyclophosphamide can be decreased when combined with Cyclosporine.
Cyproterone acetateCyclophosphamide may increase the cardiotoxic activities of Cyproterone acetate.
CytarabineCyclophosphamide may increase the cardiotoxic activities of Cytarabine.
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Cyclophosphamide.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Cyclophosphamide.
DabrafenibCyclophosphamide may increase the cardiotoxic activities of Dabrafenib.
DabrafenibThe serum concentration of Cyclophosphamide can be decreased when it is combined with Dabrafenib.
DacarbazineCyclophosphamide may increase the cardiotoxic activities of Dacarbazine.
DactinomycinCyclophosphamide may increase the cardiotoxic activities of Dactinomycin.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Cyclophosphamide.
DaratumumabCyclophosphamide may increase the cardiotoxic activities of Daratumumab.
DarifenacinThe metabolism of Cyclophosphamide can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Cyclophosphamide can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Cyclophosphamide can be increased when it is combined with Dasatinib.
DasatinibCyclophosphamide may increase the cardiotoxic activities of Dasatinib.
DaunorubicinCyclophosphamide may increase the cardiotoxic activities of Daunorubicin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Cyclophosphamide.
DecitabineCyclophosphamide may increase the cardiotoxic activities of Decitabine.
DeferasiroxThe serum concentration of Cyclophosphamide can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Cyclophosphamide can be decreased when combined with Delavirdine.
Denileukin diftitoxCyclophosphamide may increase the cardiotoxic activities of Denileukin diftitox.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cyclophosphamide.
DesipramineThe metabolism of Cyclophosphamide can be decreased when combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cyclophosphamide.
DexamethasoneCyclophosphamide may increase the cardiotoxic activities of Dexamethasone.
DexamethasoneThe serum concentration of Cyclophosphamide can be decreased when it is combined with Dexamethasone.
DexrazoxaneCyclophosphamide may increase the cardiotoxic activities of Dexrazoxane.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Cyclophosphamide.
DienogestCyclophosphamide may increase the cardiotoxic activities of Dienogest.
DiethylstilbestrolCyclophosphamide may increase the cardiotoxic activities of Diethylstilbestrol.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Cyclophosphamide.
DigoxinDigoxin may decrease the cardiotoxic activities of Cyclophosphamide.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Cyclophosphamide.
DihydroergotamineThe metabolism of Cyclophosphamide can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Cyclophosphamide.
DiltiazemThe metabolism of Cyclophosphamide can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Cyclophosphamide.
DinutuximabCyclophosphamide may increase the cardiotoxic activities of Dinutuximab.
DiphenhydramineThe metabolism of Cyclophosphamide can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Cyclophosphamide.
DocetaxelCyclophosphamide may increase the cardiotoxic activities of Docetaxel.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cyclophosphamide.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Cyclophosphamide.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cyclophosphamide.
DoxorubicinThe metabolism of Cyclophosphamide can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Cyclophosphamide can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Cyclophosphamide can be decreased when combined with Dronedarone.
DuloxetineThe metabolism of Cyclophosphamide can be decreased when combined with Duloxetine.
EcabetThe risk or severity of adverse effects can be increased when Ecabet is combined with Cyclophosphamide.
EcabetCyclophosphamide may increase the cardiotoxic activities of Ecabet.
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Cyclophosphamide.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cyclophosphamide.
efaproxiralCyclophosphamide may increase the cardiotoxic activities of efaproxiral.
EfavirenzThe serum concentration of Cyclophosphamide can be decreased when it is combined with Efavirenz.
EflornithineCyclophosphamide may increase the cardiotoxic activities of Eflornithine.
EG009Cyclophosphamide may increase the cardiotoxic activities of EG009.
ElafinThe risk or severity of adverse effects can be increased when Elafin is combined with Cyclophosphamide.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Cyclophosphamide.
EliglustatThe metabolism of Cyclophosphamide can be decreased when combined with Eliglustat.
ElsamitrucinCyclophosphamide may increase the cardiotoxic activities of Elsamitrucin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Cyclophosphamide.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Cyclophosphamide.
EnalkirenThe risk or severity of adverse effects can be increased when Enalkiren is combined with Cyclophosphamide.
EndostatinCyclophosphamide may increase the cardiotoxic activities of Endostatin.
EnoxacinCyclophosphamide may increase the cardiotoxic activities of Enoxacin.
EnrofloxacinCyclophosphamide may increase the cardiotoxic activities of Enrofloxacin.
EnzalutamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Cyclophosphamide.
EpirubicinCyclophosphamide may increase the cardiotoxic activities of Epirubicin.
Epothilone BCyclophosphamide may increase the cardiotoxic activities of Epothilone B.
EribulinCyclophosphamide may increase the cardiotoxic activities of Eribulin.
ErlotinibCyclophosphamide may increase the cardiotoxic activities of Erlotinib.
ErythromycinThe metabolism of Cyclophosphamide can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Cyclophosphamide.
Eslicarbazepine acetateThe serum concentration of Cyclophosphamide can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Esomeprazole.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Cyclophosphamide.
EstramustineCyclophosphamide may increase the cardiotoxic activities of Estramustine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Cyclophosphamide.
EstroneThe serum concentration of Estrone can be increased when it is combined with Cyclophosphamide.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Cyclophosphamide.
Ethiodized oilCyclophosphamide may increase the cardiotoxic activities of Ethiodized oil.
Ethyl carbamateCyclophosphamide may increase the cardiotoxic activities of Ethyl carbamate.
EtoposideCyclophosphamide may increase the cardiotoxic activities of Etoposide.
EtravirineThe serum concentration of Cyclophosphamide can be decreased when it is combined with Etravirine.
EverolimusCyclophosphamide may increase the cardiotoxic activities of Everolimus.
ExemestaneCyclophosphamide may increase the cardiotoxic activities of Exemestane.
exisulindCyclophosphamide may increase the cardiotoxic activities of exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Cyclophosphamide.
FelodipineThe metabolism of Cyclophosphamide can be decreased when combined with Felodipine.
FenretinideCyclophosphamide may increase the cardiotoxic activities of Fenretinide.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Cyclophosphamide.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Cyclophosphamide.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Cyclophosphamide.
FilgrastimThe risk or severity of adverse effects can be increased when Filgrastim is combined with Cyclophosphamide.
FingolimodCyclophosphamide may increase the immunosuppressive activities of Fingolimod.
FlavopiridolCyclophosphamide may increase the cardiotoxic activities of Flavopiridol.
FleroxacinCyclophosphamide may increase the cardiotoxic activities of Fleroxacin.
FloxuridineCyclophosphamide may increase the cardiotoxic activities of Floxuridine.
FloxuridineThe metabolism of Cyclophosphamide can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Fluconazole.
FludarabineCyclophosphamide may increase the cardiotoxic activities of Fludarabine.
FlumequineCyclophosphamide may increase the cardiotoxic activities of Flumequine.
FluorouracilCyclophosphamide may increase the cardiotoxic activities of Fluorouracil.
FluorouracilThe metabolism of Cyclophosphamide can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Cyclophosphamide can be decreased when combined with Fluoxetine.
FlutamideCyclophosphamide may increase the cardiotoxic activities of Flutamide.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Cyclophosphamide.
FluvastatinThe metabolism of Cyclophosphamide can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Cyclophosphamide can be decreased when combined with Fluvoxamine.
FormestaneCyclophosphamide may increase the cardiotoxic activities of Formestane.
FormycinCyclophosphamide may increase the cardiotoxic activities of Formycin.
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Cyclophosphamide.
FosaprepitantThe serum concentration of Cyclophosphamide can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Cyclophosphamide.
FosphenytoinThe metabolism of Cyclophosphamide can be increased when combined with Fosphenytoin.
FotemustineCyclophosphamide may increase the cardiotoxic activities of Fotemustine.
FulvestrantCyclophosphamide may increase the cardiotoxic activities of Fulvestrant.
FumagillinCyclophosphamide may increase the cardiotoxic activities of Fumagillin.
Fusidic AcidThe serum concentration of Cyclophosphamide can be increased when it is combined with Fusidic Acid.
Gallium nitrateCyclophosphamide may increase the cardiotoxic activities of Gallium nitrate.
GarenoxacinCyclophosphamide may increase the cardiotoxic activities of Garenoxacin.
GatifloxacinCyclophosphamide may increase the cardiotoxic activities of Gatifloxacin.
GefitinibCyclophosphamide may increase the cardiotoxic activities of Gefitinib.
GeldanamycinThe risk or severity of adverse effects can be increased when Geldanamycin is combined with Cyclophosphamide.
GeldanamycinCyclophosphamide may increase the cardiotoxic activities of Geldanamycin.
GemcitabineCyclophosphamide may increase the cardiotoxic activities of Gemcitabine.
GemfibrozilThe metabolism of Cyclophosphamide can be decreased when combined with Gemfibrozil.
GemifloxacinCyclophosphamide may increase the cardiotoxic activities of Gemifloxacin.
Gemtuzumab ozogamicinCyclophosphamide may increase the cardiotoxic activities of Gemtuzumab ozogamicin.
GenisteinCyclophosphamide may increase the cardiotoxic activities of Genistein.
Ginsenoside CCyclophosphamide may increase the cardiotoxic activities of Ginsenoside C.
GM6001The risk or severity of adverse effects can be increased when GM6001 is combined with Cyclophosphamide.
GoserelinCyclophosphamide may increase the cardiotoxic activities of Goserelin.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Cyclophosphamide.
GrepafloxacinCyclophosphamide may increase the cardiotoxic activities of Grepafloxacin.
HadacidinCyclophosphamide may increase the cardiotoxic activities of Hadacidin.
HalofuginoneCyclophosphamide may increase the cardiotoxic activities of Halofuginone.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Cyclophosphamide.
HaloperidolThe metabolism of Cyclophosphamide can be decreased when combined with Haloperidol.
HexestrolCyclophosphamide may increase the cardiotoxic activities of Hexestrol.
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Cyclophosphamide.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cyclophosphamide.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Cyclophosphamide.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Cyclophosphamide.
Hydroxyprogesterone caproateCyclophosphamide may increase the cardiotoxic activities of Hydroxyprogesterone caproate.
HydroxyureaCyclophosphamide may increase the cardiotoxic activities of Hydroxyurea.
IbrutinibCyclophosphamide may increase the cardiotoxic activities of Ibrutinib.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Cyclophosphamide.
IdarubicinCyclophosphamide may increase the cardiotoxic activities of Idarubicin.
IdelalisibThe serum concentration of Cyclophosphamide can be increased when it is combined with Idelalisib.
IdelalisibCyclophosphamide may increase the cardiotoxic activities of Idelalisib.
IfosfamideCyclophosphamide may increase the cardiotoxic activities of Ifosfamide.
ImatinibCyclophosphamide may increase the cardiotoxic activities of Imatinib.
ImatinibThe metabolism of Cyclophosphamide can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Cyclophosphamide.
ImipramineThe metabolism of Cyclophosphamide can be decreased when combined with Imipramine.
ImiquimodCyclophosphamide may increase the cardiotoxic activities of Imiquimod.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Cyclophosphamide.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Cyclophosphamide.
IndinavirThe risk or severity of adverse effects can be increased when Indinavir is combined with Cyclophosphamide.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Cyclophosphamide.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Cyclophosphamide.
Interferon beta-1aCyclophosphamide may increase the cardiotoxic activities of Interferon beta-1a.
IobenguaneCyclophosphamide may increase the cardiotoxic activities of Iobenguane.
IpilimumabCyclophosphamide may increase the cardiotoxic activities of Ipilimumab.
IrbesartanThe metabolism of Cyclophosphamide can be decreased when combined with Irbesartan.
IrinotecanCyclophosphamide may increase the cardiotoxic activities of Irinotecan.
IsavuconazoniumThe metabolism of Cyclophosphamide can be decreased when combined with Isavuconazonium.
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Cyclophosphamide.
IsoniazidThe metabolism of Cyclophosphamide can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Cyclophosphamide can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Cyclophosphamide can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Cyclophosphamide.
IxabepiloneCyclophosphamide may increase the cardiotoxic activities of Ixabepilone.
IxazomibThe risk or severity of adverse effects can be increased when Ixazomib is combined with Cyclophosphamide.
IxazomibCyclophosphamide may increase the cardiotoxic activities of Ixazomib.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Cyclophosphamide.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Cyclophosphamide.
KetoconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Ketoconazole.
KOS-1584Cyclophosphamide may increase the cardiotoxic activities of KOS-1584.
L-alanosineCyclophosphamide may increase the cardiotoxic activities of L-alanosine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Cyclophosphamide.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Cyclophosphamide.
LanreotideCyclophosphamide may increase the cardiotoxic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Cyclophosphamide.
LapatinibCyclophosphamide may increase the cardiotoxic activities of Lapatinib.
LapatinibThe metabolism of Cyclophosphamide can be decreased when combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cyclophosphamide.
LeflunomideCyclophosphamide may increase the cardiotoxic activities of Leflunomide.
LeflunomideThe metabolism of Cyclophosphamide can be decreased when combined with Leflunomide.
LenalidomideCyclophosphamide may increase the cardiotoxic activities of Lenalidomide.
LenvatinibCyclophosphamide may increase the cardiotoxic activities of Lenvatinib.
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Cyclophosphamide.
LetrozoleCyclophosphamide may increase the cardiotoxic activities of Letrozole.
LeuprolideCyclophosphamide may increase the cardiotoxic activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Cyclophosphamide.
LevofloxacinCyclophosphamide may increase the cardiotoxic activities of Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Cyclophosphamide.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Cyclophosphamide.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Cyclophosphamide.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Cyclophosphamide.
LomefloxacinCyclophosphamide may increase the cardiotoxic activities of Lomefloxacin.
LomustineCyclophosphamide may increase the cardiotoxic activities of Lomustine.
LonidamineCyclophosphamide may increase the cardiotoxic activities of Lonidamine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Cyclophosphamide.
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Cyclophosphamide.
LorcaserinThe metabolism of Cyclophosphamide can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Cyclophosphamide.
LosartanThe metabolism of Cyclophosphamide can be decreased when combined with Losartan.
LovastatinThe metabolism of Cyclophosphamide can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Cyclophosphamide can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Cyclophosphamide can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Cyclophosphamide can be decreased when combined with Lumefantrine.
LycopeneCyclophosphamide may increase the cardiotoxic activities of Lycopene.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Cyclophosphamide.
MasitinibCyclophosphamide may increase the cardiotoxic activities of Masitinib.
MasoprocolCyclophosphamide may increase the cardiotoxic activities of Masoprocol.
MaxacalcitolCyclophosphamide may increase the cardiotoxic activities of Maxacalcitol.
MDX-1106Cyclophosphamide may increase the cardiotoxic activities of MDX-1106.
MebendazoleCyclophosphamide may increase the cardiotoxic activities of Mebendazole.
MechlorethamineCyclophosphamide may increase the cardiotoxic activities of Mechlorethamine.
MedrogestoneCyclophosphamide may increase the cardiotoxic activities of Medrogestone.
Medroxyprogesterone acetateCyclophosphamide may increase the cardiotoxic activities of Medroxyprogesterone acetate.
Megestrol acetateCyclophosphamide may increase the cardiotoxic activities of Megestrol acetate.
MelphalanCyclophosphamide may increase the cardiotoxic activities of Melphalan.
MequinolCyclophosphamide may increase the cardiotoxic activities of Mequinol.
MercaptopurineCyclophosphamide may increase the cardiotoxic activities of Mercaptopurine.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Cyclophosphamide.
MethadoneThe metabolism of Cyclophosphamide can be decreased when combined with Methadone.
MethotrexateCyclophosphamide may increase the cardiotoxic activities of Methotrexate.
MethotrimeprazineThe metabolism of Cyclophosphamide can be decreased when combined with Methotrimeprazine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cyclophosphamide.
Methyl aminolevulinateCyclophosphamide may increase the cardiotoxic activities of Methyl aminolevulinate.
MethylprednisoloneCyclophosphamide may increase the cardiotoxic activities of Methylprednisolone.
MethyltestosteroneCyclophosphamide may increase the cardiotoxic activities of Methyltestosterone.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Cyclophosphamide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cyclophosphamide.
MetoprololThe metabolism of Cyclophosphamide can be decreased when combined with Metoprolol.
MGI-114Cyclophosphamide may increase the cardiotoxic activities of MGI-114.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Cyclophosphamide.
MidostaurinCyclophosphamide may increase the cardiotoxic activities of Midostaurin.
MifepristoneThe metabolism of Cyclophosphamide can be decreased when combined with Mifepristone.
MiltefosineCyclophosphamide may increase the cardiotoxic activities of Miltefosine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Cyclophosphamide.
MirabegronThe metabolism of Cyclophosphamide can be decreased when combined with Mirabegron.
MitomycinCyclophosphamide may increase the cardiotoxic activities of Mitomycin.
MitotaneThe serum concentration of Cyclophosphamide can be decreased when it is combined with Mitotane.
MitotaneCyclophosphamide may increase the cardiotoxic activities of Mitotane.
MitoxantroneCyclophosphamide may increase the cardiotoxic activities of Mitoxantrone.
MoclobemideThe metabolism of Cyclophosphamide can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Cyclophosphamide can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Cyclophosphamide.
MorphineThe serum concentration of Morphine can be increased when it is combined with Cyclophosphamide.
motexafin gadoliniumCyclophosphamide may increase the cardiotoxic activities of motexafin gadolinium.
MoxifloxacinCyclophosphamide may increase the cardiotoxic activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cyclophosphamide.
Mycophenolic acidCyclophosphamide may increase the cardiotoxic activities of Mycophenolic acid.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe risk or severity of adverse effects can be increased when N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline is combined with Cyclophosphamide.
NadololThe serum concentration of Nadolol can be increased when it is combined with Cyclophosphamide.
NafcillinThe serum concentration of Cyclophosphamide can be decreased when it is combined with Nafcillin.
Nalidixic AcidCyclophosphamide may increase the cardiotoxic activities of Nalidixic Acid.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cyclophosphamide.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Cyclophosphamide.
NatalizumabThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Cyclophosphamide.
NecitumumabCyclophosphamide may increase the cardiotoxic activities of Necitumumab.
NefazodoneThe metabolism of Cyclophosphamide can be decreased when combined with Nefazodone.
NelarabineCyclophosphamide may increase the cardiotoxic activities of Nelarabine.
NelfinavirThe risk or severity of adverse effects can be increased when Nelfinavir is combined with Cyclophosphamide.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Cyclophosphamide.
NetupitantThe serum concentration of Cyclophosphamide can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Cyclophosphamide can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Cyclophosphamide.
NicardipineThe metabolism of Cyclophosphamide can be decreased when combined with Nicardipine.
NicotineThe metabolism of Cyclophosphamide can be decreased when combined with Nicotine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Cyclophosphamide.
NiguldipineCyclophosphamide may increase the cardiotoxic activities of Niguldipine.
NilotinibCyclophosphamide may increase the cardiotoxic activities of Nilotinib.
NilotinibThe metabolism of Cyclophosphamide can be decreased when combined with Nilotinib.
NilutamideCyclophosphamide may increase the cardiotoxic activities of Nilutamide.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Cyclophosphamide.
NivolumabCyclophosphamide may increase the cardiotoxic activities of Nivolumab.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Cyclophosphamide.
nocodazoleCyclophosphamide may increase the cardiotoxic activities of nocodazole.
NorfloxacinCyclophosphamide may increase the cardiotoxic activities of Norfloxacin.
ObinutuzumabCyclophosphamide may increase the cardiotoxic activities of Obinutuzumab.
OctreotideCyclophosphamide may increase the cardiotoxic activities of Octreotide.
OfatumumabCyclophosphamide may increase the cardiotoxic activities of Ofatumumab.
OfloxacinCyclophosphamide may increase the cardiotoxic activities of Ofloxacin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Cyclophosphamide.
OlaparibCyclophosphamide may increase the cardiotoxic activities of Olaparib.
OlaparibThe metabolism of Cyclophosphamide can be decreased when combined with Olaparib.
Omacetaxine mepesuccinateCyclophosphamide may increase the cardiotoxic activities of Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Cyclophosphamide.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Cyclophosphamide.
OmeprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Omeprazole.
OprelvekinCyclophosphamide may increase the cardiotoxic activities of Oprelvekin.
OsimertinibCyclophosphamide may increase the cardiotoxic activities of Osimertinib.
OsimertinibThe serum concentration of Cyclophosphamide can be increased when it is combined with Osimertinib.
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Cyclophosphamide.
OuabainOuabain may decrease the cardiotoxic activities of Cyclophosphamide.
OxaliplatinCyclophosphamide may increase the cardiotoxic activities of Oxaliplatin.
PaclitaxelCyclophosphamide may increase the cardiotoxic activities of Paclitaxel.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cyclophosphamide.
PalbociclibThe serum concentration of Cyclophosphamide can be increased when it is combined with Palbociclib.
PalbociclibCyclophosphamide may increase the cardiotoxic activities of Palbociclib.
PalifosfamideCyclophosphamide may increase the cardiotoxic activities of Palifosfamide.
PamidronateCyclophosphamide may increase the cardiotoxic activities of Pamidronate.
PanitumumabCyclophosphamide may increase the cardiotoxic activities of Panitumumab.
PanobinostatCyclophosphamide may increase the cardiotoxic activities of Panobinostat.
PanobinostatThe metabolism of Cyclophosphamide can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Pantoprazole.
ParoxetineThe metabolism of Cyclophosphamide can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cyclophosphamide.
PefloxacinCyclophosphamide may increase the cardiotoxic activities of Pefloxacin.
PegaspargaseCyclophosphamide may increase the cardiotoxic activities of Pegaspargase.
Peginterferon alfa-2bThe serum concentration of Cyclophosphamide can be decreased when it is combined with Peginterferon alfa-2b.
PembrolizumabCyclophosphamide may increase the cardiotoxic activities of Pembrolizumab.
PemetrexedCyclophosphamide may increase the cardiotoxic activities of Pemetrexed.
PentobarbitalThe metabolism of Cyclophosphamide can be increased when combined with Pentobarbital.
PentostatinCyclophosphamide may increase the cardiotoxic activities of Pentostatin.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Cyclophosphamide.
PertuzumabCyclophosphamide may increase the cardiotoxic activities of Pertuzumab.
PhenobarbitalThe metabolism of Cyclophosphamide can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Cyclophosphamide.
Phenylacetic acidCyclophosphamide may increase the cardiotoxic activities of Phenylacetic acid.
PhenytoinThe metabolism of Cyclophosphamide can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Cyclophosphamide.
PhosphoramidonThe risk or severity of adverse effects can be increased when Phosphoramidon is combined with Cyclophosphamide.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclophosphamide.
PioglitazoneThe metabolism of Cyclophosphamide can be decreased when combined with Pioglitazone.
PipobromanCyclophosphamide may increase the cardiotoxic activities of Pipobroman.
PirfenidoneCyclophosphamide may increase the cardiotoxic activities of Pirfenidone.
PirlindoleCyclophosphamide may increase the cardiotoxic activities of Pirlindole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cyclophosphamide.
PixantroneCyclophosphamide may increase the cardiotoxic activities of Pixantrone.
PlicamycinCyclophosphamide may increase the cardiotoxic activities of Plicamycin.
PodofiloxCyclophosphamide may increase the cardiotoxic activities of Podofilox.
PodophyllinCyclophosphamide may increase the cardiotoxic activities of Podophyllin.
polyacrylic acidCyclophosphamide may increase the cardiotoxic activities of polyacrylic acid.
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Cyclophosphamide.
PomalidomideCyclophosphamide may increase the cardiotoxic activities of Pomalidomide.
PonatinibCyclophosphamide may increase the cardiotoxic activities of Ponatinib.
PorfimerCyclophosphamide may increase the cardiotoxic activities of Porfimer.
porfiromycinCyclophosphamide may increase the cardiotoxic activities of porfiromycin.
PosaconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Posaconazole.
PralatrexateCyclophosphamide may increase the cardiotoxic activities of Pralatrexate.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cyclophosphamide.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Cyclophosphamide.
PrednisoloneCyclophosphamide may increase the cardiotoxic activities of Prednisolone.
PrednisoneCyclophosphamide may increase the cardiotoxic activities of Prednisone.
PrimidoneThe metabolism of Cyclophosphamide can be increased when combined with Primidone.
PrinomastatThe risk or severity of adverse effects can be increased when Prinomastat is combined with Cyclophosphamide.
ProcarbazineCyclophosphamide may increase the cardiotoxic activities of Procarbazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Cyclophosphamide.
PromazineThe metabolism of Cyclophosphamide can be decreased when combined with Promazine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Cyclophosphamide.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cyclophosphamide.
Purine RibosideCyclophosphamide may increase the cardiotoxic activities of Purine Riboside.
PuromycinCyclophosphamide may increase the cardiotoxic activities of Puromycin.
PyrimethamineThe metabolism of Cyclophosphamide can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Cyclophosphamide can be increased when it is combined with Quazepam.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Cyclophosphamide.
QuinacrineCyclophosphamide may increase the cardiotoxic activities of Quinacrine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Cyclophosphamide.
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Cyclophosphamide.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Cyclophosphamide.
QuinidineThe metabolism of Cyclophosphamide can be decreased when combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Cyclophosphamide.
QuinineThe metabolism of Cyclophosphamide can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Rabeprazole.
Rabies vaccineThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Rabies vaccine.
Radium Ra 223 DichlorideCyclophosphamide may increase the cardiotoxic activities of Radium Ra 223 Dichloride.
RaltitrexedCyclophosphamide may increase the cardiotoxic activities of Raltitrexed.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Cyclophosphamide.
RamucirumabCyclophosphamide may increase the cardiotoxic activities of Ramucirumab.
RanibizumabCyclophosphamide may increase the cardiotoxic activities of Ranibizumab.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Cyclophosphamide.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cyclophosphamide.
RanolazineThe metabolism of Cyclophosphamide can be decreased when combined with Ranolazine.
RanpirnaseCyclophosphamide may increase the cardiotoxic activities of Ranpirnase.
RegorafenibCyclophosphamide may increase the cardiotoxic activities of Regorafenib.
RemikirenThe risk or severity of adverse effects can be increased when Remikiren is combined with Cyclophosphamide.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Cyclophosphamide.
ResveratrolCyclophosphamide may increase the cardiotoxic activities of Resveratrol.
Rhodamine 6GCyclophosphamide may increase the cardiotoxic activities of Rhodamine 6G.
RifabutinThe metabolism of Cyclophosphamide can be increased when combined with Rifabutin.
RifampicinThe metabolism of Cyclophosphamide can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Cyclophosphamide.
RifapentineThe metabolism of Cyclophosphamide can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cyclophosphamide.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Cyclophosphamide.
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Cyclophosphamide.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Cyclophosphamide.
RituximabCyclophosphamide may increase the cardiotoxic activities of Rituximab.
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Cyclophosphamide.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Cyclophosphamide.
RoflumilastRoflumilast may increase the immunosuppressive activities of Cyclophosphamide.
RolapitantThe metabolism of Cyclophosphamide can be decreased when combined with Rolapitant.
RomidepsinCyclophosphamide may increase the cardiotoxic activities of Romidepsin.
RomiplostimCyclophosphamide may increase the cardiotoxic activities of Romiplostim.
RopiniroleThe metabolism of Cyclophosphamide can be decreased when combined with Ropinirole.
RoquinimexCyclophosphamide may increase the cardiotoxic activities of Roquinimex.
RosiglitazoneThe metabolism of Cyclophosphamide can be decreased when combined with Rosiglitazone.
RubitecanCyclophosphamide may increase the cardiotoxic activities of Rubitecan.
RuxolitinibCyclophosphamide may increase the cardiotoxic activities of Ruxolitinib.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Cyclophosphamide.
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Cyclophosphamide.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Cyclophosphamide.
SargramostimThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim.
SatraplatinCyclophosphamide may increase the cardiotoxic activities of Satraplatin.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Cyclophosphamide.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Cyclophosphamide.
SecobarbitalThe metabolism of Cyclophosphamide can be increased when combined with Secobarbital.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Cyclophosphamide.
SeliciclibCyclophosphamide may increase the cardiotoxic activities of Seliciclib.
SemaxanibCyclophosphamide may increase the cardiotoxic activities of Semaxanib.
SeocalcitolCyclophosphamide may increase the cardiotoxic activities of Seocalcitol.
SertralineThe metabolism of Cyclophosphamide can be decreased when combined with Sertraline.
SildenafilThe metabolism of Cyclophosphamide can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cyclophosphamide.
SiltuximabThe serum concentration of Cyclophosphamide can be decreased when it is combined with Siltuximab.
SiltuximabCyclophosphamide may increase the cardiotoxic activities of Siltuximab.
SimeprevirThe serum concentration of Cyclophosphamide can be increased when it is combined with Simeprevir.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclophosphamide.
SirolimusCyclophosphamide may increase the cardiotoxic activities of Sirolimus.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Cyclophosphamide.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Cyclophosphamide.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Cyclophosphamide.
SonidegibCyclophosphamide may increase the cardiotoxic activities of Sonidegib.
SorafenibCyclophosphamide may increase the cardiotoxic activities of Sorafenib.
SorafenibThe metabolism of Cyclophosphamide can be decreased when combined with Sorafenib.
SparfloxacinCyclophosphamide may increase the cardiotoxic activities of Sparfloxacin.
Sparfosic acidCyclophosphamide may increase the cardiotoxic activities of Sparfosic acid.
SparsomycinCyclophosphamide may increase the cardiotoxic activities of Sparsomycin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Cyclophosphamide.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Cyclophosphamide.
squalamineCyclophosphamide may increase the cardiotoxic activities of squalamine.
SRT501Cyclophosphamide may increase the cardiotoxic activities of SRT501.
St. John's WortThe serum concentration of Cyclophosphamide can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Cyclophosphamide can be increased when it is combined with Stiripentol.
StreptozocinCyclophosphamide may increase the cardiotoxic activities of Streptozocin.
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Cyclophosphamide.
SulfadiazineThe metabolism of Cyclophosphamide can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Cyclophosphamide can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Cyclophosphamide can be decreased when combined with Sulfisoxazole.
SulindacCyclophosphamide may increase the cardiotoxic activities of Sulindac.
SunitinibCyclophosphamide may increase the cardiotoxic activities of Sunitinib.
SuraminCyclophosphamide may increase the cardiotoxic activities of Suramin.
SwainsonineCyclophosphamide may increase the cardiotoxic activities of Swainsonine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Cyclophosphamide.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Cyclophosphamide.
TamoxifenCyclophosphamide may increase the cardiotoxic activities of Tamoxifen.
TamoxifenThe metabolism of Cyclophosphamide can be decreased when combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Cyclophosphamide.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Cyclophosphamide.
TegafurCyclophosphamide may increase the cardiotoxic activities of Tegafur.
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Cyclophosphamide.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Cyclophosphamide.
TelithromycinThe metabolism of Cyclophosphamide can be decreased when combined with Telithromycin.
TemafloxacinCyclophosphamide may increase the cardiotoxic activities of Temafloxacin.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Cyclophosphamide.
TemozolomideCyclophosphamide may increase the cardiotoxic activities of Temozolomide.
TemsirolimusCyclophosphamide may increase the cardiotoxic activities of Temsirolimus.
TeniposideCyclophosphamide may increase the cardiotoxic activities of Teniposide.
TerbinafineThe metabolism of Cyclophosphamide can be decreased when combined with Terbinafine.
TeriflunomideThe metabolism of Cyclophosphamide can be decreased when combined with Teriflunomide.
TestolactoneCyclophosphamide may increase the cardiotoxic activities of Testolactone.
TetrathiomolybdateCyclophosphamide may increase the cardiotoxic activities of Tetrathiomolybdate.
TezacitabineCyclophosphamide may increase the cardiotoxic activities of Tezacitabine.
ThalidomideCyclophosphamide may increase the cardiotoxic activities of Thalidomide.
ThioridazineThe metabolism of Cyclophosphamide can be decreased when combined with Thioridazine.
ThiorphanThe risk or severity of adverse effects can be increased when Thiorphan is combined with Cyclophosphamide.
ThiotepaCyclophosphamide may increase the cardiotoxic activities of Thiotepa.
ThiotepaThe metabolism of Cyclophosphamide can be decreased when combined with Thiotepa.
ThymalfasinCyclophosphamide may increase the cardiotoxic activities of Thymalfasin.
TiboloneCyclophosphamide may increase the cardiotoxic activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Cyclophosphamide.
TicagrelorThe metabolism of Cyclophosphamide can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Cyclophosphamide can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Cyclophosphamide.
TioguanineCyclophosphamide may increase the cardiotoxic activities of Tioguanine.
TipifarnibCyclophosphamide may increase the cardiotoxic activities of Tipifarnib.
TipranavirThe risk or severity of adverse effects can be increased when Tipranavir is combined with Cyclophosphamide.
TirapazamineCyclophosphamide may increase the cardiotoxic activities of Tirapazamine.
TocilizumabThe serum concentration of Cyclophosphamide can be decreased when it is combined with Tocilizumab.
TofacitinibCyclophosphamide may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe metabolism of Cyclophosphamide can be decreased when combined with Tolbutamide.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cyclophosphamide.
TopiramateThe metabolism of Cyclophosphamide can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cyclophosphamide.
ToremifeneCyclophosphamide may increase the cardiotoxic activities of Toremifene.
TositumomabCyclophosphamide may increase the cardiotoxic activities of Tositumomab.
TrabectedinCyclophosphamide may increase the cardiotoxic activities of Trabectedin.
TrametinibCyclophosphamide may increase the cardiotoxic activities of Trametinib.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Cyclophosphamide.
TranylcypromineThe metabolism of Cyclophosphamide can be decreased when combined with Tranylcypromine.
TrastuzumabTrastuzumab may increase the neutropenic activities of Cyclophosphamide.
TrastuzumabCyclophosphamide may increase the cardiotoxic activities of Trastuzumab.
Trastuzumab emtansineCyclophosphamide may increase the cardiotoxic activities of Trastuzumab emtansine.
TretinoinCyclophosphamide may increase the cardiotoxic activities of Tretinoin.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Cyclophosphamide.
TrifluridineCyclophosphamide may increase the cardiotoxic activities of Trifluridine.
TrilostaneCyclophosphamide may increase the cardiotoxic activities of Trilostane.
TrimethoprimThe metabolism of Cyclophosphamide can be decreased when combined with Trimethoprim.
TrimetrexateCyclophosphamide may increase the cardiotoxic activities of Trimetrexate.
TriptorelinCyclophosphamide may increase the cardiotoxic activities of Triptorelin.
TrovafloxacinCyclophosphamide may increase the cardiotoxic activities of Trovafloxacin.
TroxacitabineCyclophosphamide may increase the cardiotoxic activities of Troxacitabine.
TTNPBCyclophosphamide may increase the cardiotoxic activities of TTNPB.
TubercidinCyclophosphamide may increase the cardiotoxic activities of Tubercidin.
UbenimexThe risk or severity of adverse effects can be increased when Ubenimex is combined with Cyclophosphamide.
UbenimexCyclophosphamide may increase the cardiotoxic activities of Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Cyclophosphamide.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Cyclophosphamide.
Uracil mustardCyclophosphamide may increase the cardiotoxic activities of Uracil mustard.
Valproic AcidThe metabolism of Cyclophosphamide can be decreased when combined with Valproic Acid.
ValrubicinCyclophosphamide may increase the cardiotoxic activities of Valrubicin.
ValsartanThe metabolism of Cyclophosphamide can be decreased when combined with Valsartan.
VandetanibCyclophosphamide may increase the cardiotoxic activities of Vandetanib.
VapreotideCyclophosphamide may increase the cardiotoxic activities of Vapreotide.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Cyclophosphamide.
VeliparibCyclophosphamide may increase the cardiotoxic activities of Veliparib.
VemurafenibCyclophosphamide may increase the cardiotoxic activities of Vemurafenib.
VenlafaxineThe metabolism of Cyclophosphamide can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Cyclophosphamide.
VerapamilThe metabolism of Cyclophosphamide can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Cyclophosphamide.
VerteporfinCyclophosphamide may increase the cardiotoxic activities of Verteporfin.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Cyclophosphamide.
VinblastineCyclophosphamide may increase the cardiotoxic activities of Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Cyclophosphamide.
VindesineCyclophosphamide may increase the cardiotoxic activities of Vindesine.
VinorelbineCyclophosphamide may increase the cardiotoxic activities of Vinorelbine.
VismodegibCyclophosphamide may increase the cardiotoxic activities of Vismodegib.
Vitamin ACyclophosphamide may increase the cardiotoxic activities of Vitamin A.
VoriconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Voriconazole.
VorinostatCyclophosphamide may increase the cardiotoxic activities of Vorinostat.
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Cyclophosphamide.
ZafirlukastThe metabolism of Cyclophosphamide can be decreased when combined with Zafirlukast.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Cyclophosphamide.
ZiprasidoneThe metabolism of Cyclophosphamide can be decreased when combined with Ziprasidone.
Food Interactions
  • Drink liberally- 2 to 3 liters/day.
  • Take with food to reduce irritation.

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Khan O, Middleton MR: The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors. Expert Opin Investig Drugs. 2007 Oct;16(10):1573-84. [PubMed:17922622 ]
  4. Schmidt E, Tony HP, Brocker EB, Kneitz C: Sun-induced life-threatening lupus nephritis. Ann N Y Acad Sci. 2007 Jun;1108:35-40. [PubMed:17893968 ]
  5. Zhang QH, Wu CF, Duan L, Yang JY: Protective effects of total saponins from stem and leaf of Panax ginseng against cyclophosphamide-induced genotoxicity and apoptosis in mouse bone marrow cells and peripheral lymphocyte cells. Food Chem Toxicol. 2008 Jan;46(1):293-302. Epub 2007 Aug 23. [PubMed:17904265 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preiss R, Schmidt R, Baumann F, Hanschmann H, Hauss J, Geissler F, Pahlig H, Ratzewiss B: Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92. Epub 2002 Jun 11. [PubMed:12136253 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preiss R, Schmidt R, Baumann F, Hanschmann H, Hauss J, Geissler F, Pahlig H, Ratzewiss B: Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92. Epub 2002 Jun 11. [PubMed:12136253 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD: Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics. 2008 Jun;18(6):515-23. doi: 10.1097/FPC.0b013e3282fc9766. [PubMed:18496131 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603. [PubMed:11743742 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23